Related Experiment Videos
[Immunotherapy of malignant diseases]
Bulletin Du Cancer
|January 1, 1995
Summary
Cancer immunotherapy evolved from nonspecific treatments to targeted biological therapies like cytokines and monoclonal antibodies. These advancements represent significant progress in biological cancer treatment.
Area of Science:
- Oncology
- Immunology
- Biotherapy
Context:
- Cancer immunotherapy has a history dating back to the 1950s.
- Early treatments utilized nonspecific immune system stimulants.
- Recent advancements include cytokines and monoclonal antibodies.
Purpose:
- To provide an overview of the historical development and recent advancements in cancer immunotherapy.
- To highlight the transition from nonspecific to targeted biological therapies for cancer treatment.
Summary:
- The evolution of cancer immunotherapy began with nonspecific agents like BCG and Corynebacterium parvum.
- Modern approaches involve cytokines (e.g., interferons, interleukin-2) and monoclonal antibodies.
- These newer methods signify a progressive step in the biological therapy of cancer.
Impact:
- Demonstrates the progression of cancer treatment strategies.
- Highlights the increasing role of biological therapies in oncology.
- Sets the stage for future innovations in immunotherapy research.